Electrophysiological assays using oocytes that express human enac and the use of phenamil to improve the effect of enac enhancers in assays using membrane potential reporting dyes

Patent metadata

Field	Value
Publication number	US-9459259-B2
Application number	US-56375804-A
Country	US
Kind code	B2
Filing date	Jul 9, 2004
Priority date	May 1, 2001
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.

First claim

What is claimed:

1. A mammalian cell-based high throughput assay for the profiling and screening of putative modulators of a human epithelial sodium channel (ENaC) comprising:
(i) contacting a test cell expressing delta, beta and gamma subunits, wherein said beta subunit has at least 99% sequence identity with the amino acid sequence of human ENaC beta subunit encoded by SEQ ID NO: 2, said gamma subunit has at least 99% sequence identity with the amino acid sequence of human ENaC encoded by SEQ ID NO: 3, and the delta subunit has at least 99% sequence identity with the amino acid sequence of human ENaC delta subunit encoded by SEQ ID NO: 7;
(ii) preloading the test cell with a membrane potential fluorescent dye or a sodium fluorescent dye along with at least one known ENaC inhibitor under conditions that at least partially inhibits human ENaC function, and thereafter contacting the test cell with at least one putative human ENaC modulator compound in the presence of lithium; and
(iii) monitoring fluorescence emitted by the test cell in the presence of the putative modulator/ENaC interactions compared to fluorescence emitted by the test cell in the absence of the putative modulator compound in order to determine the extent of human ENaC modulation of the putative human ENaC modulator compound, and based on said comparison in detected fluorescence determining whether said compound modulates the human ENaC channel.

2. The method of claim 1 , wherein the known human ENaC inhibitor is an amiloride derivative.

3. The method of claim 2 wherein said amiloride derivative is Phenamil.

4. The method of claim 1 in which the test cell is selected from the group consisting of MDCK, BHK, COS, NIH3T3, Swiss3T3 and CHO.

5. The method of claim 1 in which a said method is used to identify a compound as one which particularly modulates taste based on a detectable change in fluorescence.

6. The method of claim 5 , wherein said taste is salty taste.

7. The method of claim 1 in which said test cells are seeded onto a well of a multi-well test plate.

8. The method of claim 7 , wherein said test cells are contacted with a putative modulator by adding said putative modulation to the well of said multi-well test plate.

9. The method of claim 8 , wherein said test cells are loaded with a membrane potential dye that allows for changes in fluorescence to be detected.

10. The method of claim 1 , wherein said human ENaC subunits all comprise human ENaC subunits cloned from human kidney cDNA.

11. The method of claim 1 , wherein said human ENaC subunits comprise human ENaC subunits cloned from human lung cDNA.

12. The method of claim 1 , wherein the human ENaC is a human ENaC that is encoded by human ENaC DNA sequences cloned from human taste cell cDNA.

13. The method of claim 1 , wherein a fluorescence plate reader is used to monitor changes in fluorescence.

14. The method of claim 1 , wherein a voltage imaging plate reader is used to monitor changes in fluorescence.

15. The assay of claim 1 wherein the membrane potential dye is selected from the group consisting of Pyridinium, 4-(2-(6-(dibutylamino)-2-naphthalenyl)ethenyl)-1-(3-sulfopropyl))-, hydroxide, inner salt, (bis-(1,2-dibarbituric acid)-trimethine oxanol), (bis-(1,2-dibarbituric acid)-trimethine oxanol; 1,2-dietradecanoyl-sn-glycerol-3-phosphoethanolmine, triethylammonium salt; and (1,3-Benzenedicarboxylic acid, 4,4′-[1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diylbis(5-methoxy-6,1-2-benzofurandiyl)]bis-,tetrakis[(acetyloxy)methyl]ester.

16. The assay of claim 1 , wherein said beta subunit has the amino acid sequence of human ENaC beta subunit encoded by SEQ ID NO: 2, said gamma subunit has the amino acid sequence of human ENaC encoded by SEQ ID NO: 3, and the delta subunit has the amino acid sequence of human ENaC delta subunit encoded by SEQ ID NO:7.

Assignees

• Servant Guy
• Chang Hong
• Redcrow Cyril
• Ray Sumita
• Clark Imran
• Moyer Bryan
• Senomyx Inc

Inventors

• Servant Guy
• Chang Hong
• Redcrow Cyril
• Ray Sumita
• Clark Imran
• Moyer Bryan

Classifications

• G01N33/6872 Primary

  Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

• G01N33/5044

  involving specific cell types · CPC title

• G01N2500/10

  involving cells · CPC title

• G01N33/50

  Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title

• C12N2503/02

  Drug screening · CPC title